Warning: Undefined array key "HTTP_ACCEPT_LANGUAGE" in /home/u596154002/domains/usbusinessreviews.com/public_html/wp-includes/load.php on line 2057

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the rank-math domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u596154002/domains/usbusinessreviews.com/public_html/wp-includes/functions.php on line 6114
Net profit rises 14.22% to Rs 116.5 crore - Best Business Review Site 2024

Net profit rises 14.22% to Rs 116.5 crore

[ad_1]


Syngene International Ltd on Tuesday reported a 14.22 per cent increase in consolidated net profit at Rs 116.5 crore in the September quarter.


The company had posted a consolidated net profit of Rs 102 crore in the year-ago period, Syngene International said in a regulatory filing.


Consolidated revenue from operations were at Rs 910.1 crore as compared to Rs 768.1 crore in the year-ago period, it added.


The company’s total expenses rose to Rs 773.6 crore in the second quarter of the current fiscal as against Rs 653.5 crore a year ago.


Syngene International Managing Director and CEO Jonathan Hunt said the company posted strong results for the second quarter and first half of the ongoing financial year, particularly in its development and manufacturing services.


“In development services, we also added a new non-GMP capability centre to meet market demand for agile, cost-efficient, early phase development and scale-up services,” he said.


“In manufacturing, we made good progress on our long-term biologics partnership with Zoetis, as well as commissioning a state-of-the-art, digitally enabled quality control laboratory to support our growing biologics operations,” Hunt said.


The acquisition of a multi-modal facility from Stelis Biopharma Ltd, announced last quarter, is progressing, he added.


On the outlook, Hunt said, “Long-term sector fundamentals remain strong and we expect continued growth but at a lower level in the second half of the year… the short-term slowing in the US biotech segment is reflected in our latest outlook.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Oct 17 2023 | 9:46 PM IST

[ad_2]

Source link

slot gacor slot gacor togel macau slot hoki bandar togel slot dana slot mahjong link slot link slot777 slot gampang maxwin slot hoki slot mahjong slot maxwin slot mpo slot777 slot toto slot toto situs toto toto slot situs toto situs toto situs toto situs toto slot88 toto slot slot gacor thailand slot bet receh situs toto situs toto slot toto slot situs toto situs toto situs toto situs togel macau toto slot slot demo slot pulsa slot pragmatic situs toto deposit dana 10k surga slot toto slot link situs toto situs toto slot situs toto situs toto slot777 slot gacor situs toto slot slot pulsa 10k toto togel situs toto slot situs toto slot gacor terpercaya slot dana slot gacor pay4d agen sbobet kedai168 kedai168 deposit pulsa situs toto slot pulsa situs toto slot pulsa situs toto situs toto situs toto slot dana toto slot situs toto slot pulsa toto slot situs toto slot pulsa situs toto situs toto situs toto toto slot toto slot slot toto akun pro maxwin situs toto slot gacor maxwin slot gacor maxwin situs toto slot slot depo 10k toto slot toto slot situs toto situs toto toto slot toto slot toto slot toto togel slot toto togel situs toto situs toto toto slot slot gacor slot gacor slot gacor situs toto situs toto cytotec toto slot situs toto situs toto toto slot situs toto situs toto slot gacor maxwin slot gacor maxwin link slot 10k slot gacor maxwin slot gacor slot pulsa situs slot 10k slot 10k toto slot toto slot situs toto situs toto situs toto bandar togel 4d toto slot toto slot